Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis
Although biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to...
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Medical Journals Sweden
2025-06-01
|
| Series: | Acta Dermato-Venereologica |
| Subjects: | |
| Online Access: | https://medicaljournalssweden.se/actadv/article/view/42767 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849423127356899328 |
|---|---|
| author | Linda T.H. Godding Marieke M.B. Seyger Albert Duvetorp Marisol E. Otero Paul M. Ossenkoppele Annet M. Oostveen M. Birgitte Visch Ella A.M. van der Voort John E.M. Körver Lizelotte J.M.T. Weppner-Parren Maartje A.M. Berends W. Peter Arnold Sharon R.P. Dodemont Astrid L.A. Kuijpers Johannes M. Mommers Femke M. Homan Antoni H. Gostynski Berit Velstra Marloes M. Kleinpenning Martijn B.A. van Doorn Romy R.M.C. Keijsers Else N. Kop Inge M. Haeck Judith H.J. Hendricksen-Roelofzen Douwe Vellinga Elke M.G.J. de Jong Juul M.P.A. van den Reek |
| author_facet | Linda T.H. Godding Marieke M.B. Seyger Albert Duvetorp Marisol E. Otero Paul M. Ossenkoppele Annet M. Oostveen M. Birgitte Visch Ella A.M. van der Voort John E.M. Körver Lizelotte J.M.T. Weppner-Parren Maartje A.M. Berends W. Peter Arnold Sharon R.P. Dodemont Astrid L.A. Kuijpers Johannes M. Mommers Femke M. Homan Antoni H. Gostynski Berit Velstra Marloes M. Kleinpenning Martijn B.A. van Doorn Romy R.M.C. Keijsers Else N. Kop Inge M. Haeck Judith H.J. Hendricksen-Roelofzen Douwe Vellinga Elke M.G.J. de Jong Juul M.P.A. van den Reek |
| author_sort | Linda T.H. Godding |
| collection | DOAJ |
| description | Although biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17- and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data. Using Dutch list prices and discounts on adalimumab’s and ustekinumab’s originator prices because of biosimilar availability, adalimumab showed the lowest 1-year CPR across all responder definitions. Among biologics without biosimilar availability, the lowest CPRs were seen for brodalumab and guselkumab. Overall, the cost-per-PASI ≤ 3-responder was, across all biologics, more homogeneous than the CPR based on relative PASIs. Similar patterns were seen when using Swedish prices, which are, in contrast to Dutch prices, transparent. The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy.
|
| format | Article |
| id | doaj-art-77e13c9e6d3c45deb59377dd5d46238d |
| institution | Kabale University |
| issn | 0001-5555 1651-2057 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Medical Journals Sweden |
| record_format | Article |
| series | Acta Dermato-Venereologica |
| spelling | doaj-art-77e13c9e6d3c45deb59377dd5d46238d2025-08-20T03:30:45ZengMedical Journals SwedenActa Dermato-Venereologica0001-55551651-20572025-06-0110510.2340/actadv.v105.42767Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of PsoriasisLinda T.H. Godding0Marieke M.B. Seyger1Albert Duvetorp2Marisol E. Otero3Paul M. Ossenkoppele4Annet M. Oostveen5M. Birgitte Visch6Ella A.M. van der Voort7John E.M. Körver8Lizelotte J.M.T. Weppner-Parren9Maartje A.M. Berends10W. Peter Arnold11Sharon R.P. Dodemont12Astrid L.A. Kuijpers13Johannes M. Mommers14Femke M. Homan15Antoni H. Gostynski16Berit Velstra17Marloes M. Kleinpenning18Martijn B.A. van Doorn19Romy R.M.C. Keijsers20Else N. Kop21Inge M. Haeck22Judith H.J. Hendricksen-Roelofzen23Douwe Vellinga24Elke M.G.J. de Jong25Juul M.P.A. van den Reek26Department of Dermatology, Radboud University Medical Centre, Nijmegen, The NetherlandsDepartment of Dermatology, Radboud University Medical Centre, Nijmegen, The NetherlandsLeo Foundation Skin Immunology Research Center, Department of Immunology and Microbiology, University of Copenhagen, Copenhagen, Denmark; Department of Clinical Sciences Malmö, Lund University, Lund, Sweden; Department of Dermatology Malmö, Skåne University Hospital, Region Skåne, Malmö, SwedenDepartment of Dermatology, Radboud University Medical Centre, Nijmegen, The NetherlandsDepartment of Dermatology, Ziekenhuisgroep Twente, Almelo/Hengelo, The NetherlandsDepartment of Dermatology, Gelre Ziekenhuizen, Apeldoorn/Zutphen, The NetherlandsDepartment of Dermatology, Ziekenhuis Rijnstate, Arnhem, The NetherlandsDepartment of Dermatology/dermaTeam Research, Bravis, Bergen op Zoom, The NetherlandsDepartment of Dermatology, Amphia ziekenhuis, Breda, The NetherlandsDepartment of Dermatology, Jeroen Bosch Ziekenhuis, ’s-Hertogenbosch, The NetherlandsDepartment of Dermatology, Slingeland Ziekenhuis, Doetinchem, The NetherlandsDepartment of Dermatology, Ziekenhuis Gelderse Vallei, Ede, The NetherlandsDepartment of Dermatology, Catharina Ziekenhuis, Eindhoven, The NetherlandsDepartment of Dermatology, Máxima MC, Eindhoven, The NetherlandsDepartment of Dermatology, Anna Ziekenhuis, Geldrop, The NetherlandsDepartment of Dermatology, Ziekenhuisgroep Twente, Almelo/Hengelo, The NetherlandsDepartment of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands; GROW, Research Institute for Oncology and Reproduction, Maastricht University, Maastricht, The NetherlandsDepartment of Dermatology, St Antonius Ziekenhuis, Nieuwegein, The NetherlandsDepartment of Dermatology, Canisius Wilhelmina Ziekenhuis, Nijmegen, The NetherlandsDepartment of Dermatology, Erasmus MC, Rotterdam, The NetherlandsDepartment of Dermatology, Zuyderland Medisch Centrum, Sittard-Geleen/Heerlen, The NetherlandsDepartment of Dermatology, Bernhoven, Uden, The NetherlandsDepartment of Dermatology, Utrecht Medisch Centrum, Utrecht, The NetherlandsDepartment of Dermatology, Streekziekenhuis Koningin Beatrix, Winterswijk, The NetherlandsDepartment of Dermatology, Alrijne hospital, Leiderdorp, The NetherlandsDepartment of Dermatology, Radboud University Medical Centre, Nijmegen, The NetherlandsDepartment of Dermatology, Radboud University Medical Centre, Nijmegen, The NetherlandsAlthough biologics have revolutionized psoriasis treatment, they pose a significant burden on the healthcare budget. With the wide range of biologics available and the increasing number of biosimilars, insights into the real-world cost per responder (CPR) are required. Therefore, this study aims to evaluate the real-world CPR of adalimumab, ustekinumab, IL17- and IL23-inhibitors, incorporating both relative (Psoriasis Area and Severity Index; PASI75/90/100) and absolute (PASI ≤ 3/ ≤ 1) responder definitions and real-world dose adjustments. Tildrakizumab and bimekizumab were excluded due to limited data. Using Dutch list prices and discounts on adalimumab’s and ustekinumab’s originator prices because of biosimilar availability, adalimumab showed the lowest 1-year CPR across all responder definitions. Among biologics without biosimilar availability, the lowest CPRs were seen for brodalumab and guselkumab. Overall, the cost-per-PASI ≤ 3-responder was, across all biologics, more homogeneous than the CPR based on relative PASIs. Similar patterns were seen when using Swedish prices, which are, in contrast to Dutch prices, transparent. The relevance of using real-world data, specifically with the use of absolute PASIs instead of relative PASIs, is shown in this study. Additionally, as price fluctuations have the biggest impact on cost-effectiveness, price transparency is essential to effectively guide physicians in selecting a cost-effective treatment strategy. https://medicaljournalssweden.se/actadv/article/view/42767Biologicscost-effectivenesscost per responderobservational studiespsoriasisreal-world evidence |
| spellingShingle | Linda T.H. Godding Marieke M.B. Seyger Albert Duvetorp Marisol E. Otero Paul M. Ossenkoppele Annet M. Oostveen M. Birgitte Visch Ella A.M. van der Voort John E.M. Körver Lizelotte J.M.T. Weppner-Parren Maartje A.M. Berends W. Peter Arnold Sharon R.P. Dodemont Astrid L.A. Kuijpers Johannes M. Mommers Femke M. Homan Antoni H. Gostynski Berit Velstra Marloes M. Kleinpenning Martijn B.A. van Doorn Romy R.M.C. Keijsers Else N. Kop Inge M. Haeck Judith H.J. Hendricksen-Roelofzen Douwe Vellinga Elke M.G.J. de Jong Juul M.P.A. van den Reek Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis Acta Dermato-Venereologica Biologics cost-effectiveness cost per responder observational studies psoriasis real-world evidence |
| title | Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis |
| title_full | Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis |
| title_fullStr | Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis |
| title_full_unstemmed | Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis |
| title_short | Real-world Cost per Responder Among Different Classes of Biologics for the Treatment of Psoriasis |
| title_sort | real world cost per responder among different classes of biologics for the treatment of psoriasis |
| topic | Biologics cost-effectiveness cost per responder observational studies psoriasis real-world evidence |
| url | https://medicaljournalssweden.se/actadv/article/view/42767 |
| work_keys_str_mv | AT lindathgodding realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT mariekembseyger realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT albertduvetorp realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT marisoleotero realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT paulmossenkoppele realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT annetmoostveen realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT mbirgittevisch realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT ellaamvandervoort realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT johnemkorver realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT lizelottejmtweppnerparren realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT maartjeamberends realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT wpeterarnold realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT sharonrpdodemont realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT astridlakuijpers realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT johannesmmommers realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT femkemhoman realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT antonihgostynski realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT beritvelstra realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT marloesmkleinpenning realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT martijnbavandoorn realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT romyrmckeijsers realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT elsenkop realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT ingemhaeck realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT judithhjhendricksenroelofzen realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT douwevellinga realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT elkemgjdejong realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis AT juulmpavandenreek realworldcostperresponderamongdifferentclassesofbiologicsforthetreatmentofpsoriasis |